NCT06116578View on ClinicalTrials.gov

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

June 30, 2029

Conditions
Cancer
Interventions
DRUG

Pembrolizumab

cf Arm A

DRUG

Pembrolizumab and Olaparib

cf Arm B

DRUG

Pembrolizumab adjuvant

After surgery (adjuvant phase), all patients (Arm A and B) will receive pembrolizumab 200 mg two intravenous (IV) infusions q3w for one-year

Trial Locations (1)

94800

RECRUITING

Gustave Roussy, Villejuif

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT06116578 - Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab | Biotech Hunter | Biotech Hunter